Drug profile · INN
empagliflozin + linagliptin
GLYXAMBI
empagliflozin + linagliptin (GLYXAMBI) is an FDA-listed pharmaceutical active ingredient. Associated with Boehringer Ingelheim Pty Ltd.
TGA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — empagliflozin + linagliptin
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
empagliflozin + linagliptin (GLYXAMBI) is an FDA-listed pharmaceutical active ingredient. Associated with Boehringer Ingelheim Pty Ltd.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Frequently asked questions
What is empagliflozin + linagliptin?
empagliflozin + linagliptin (GLYXAMBI) is an FDA-listed pharmaceutical active ingredient. Associated with Boehringer Ingelheim Pty Ltd.
What is the brand name for empagliflozin + linagliptin?
GLYXAMBI is a marketed brand name for empagliflozin + linagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.